Literature DB >> 32363603

Point and interval estimation in two-stage adaptive designs with time to event data and biomarker-driven subpopulation selection.

Peter K Kimani1, Susan Todd2, Lindsay A Renfro3, Ekkehard Glimm4, Josephine N Khan5, John A Kairalla6, Nigel Stallard1.   

Abstract

In personalized medicine, it is often desired to determine if all patients or only a subset of them benefit from a treatment. We consider estimation in two-stage adaptive designs that in stage 1 recruit patients from the full population. In stage 2, patient recruitment is restricted to the part of the population, which, based on stage 1 data, benefits from the experimental treatment. Existing estimators, which adjust for using stage 1 data for selecting the part of the population from which stage 2 patients are recruited, as well as for the confirmatory analysis after stage 2, do not consider time to event patient outcomes. In this work, for time to event data, we have derived a new asymptotically unbiased estimator for the log hazard ratio and a new interval estimator with good coverage probabilities and probabilities that the upper bounds are below the true values. The estimators are appropriate for several selection rules that are based on a single or multiple biomarkers, which can be categorical or continuous.
© 2020 The Authors. Statistics in Medicine published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  adaptive threshold design; enrichment designs; stratified medicine; subgroup analysis; survival data

Mesh:

Substances:

Year:  2020        PMID: 32363603      PMCID: PMC7785132          DOI: 10.1002/sim.8557

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  33 in total

1.  Adaptive sample size calculations in group sequential trials.

Authors:  W Lehmacher; G Wassmer
Journal:  Biometrics       Date:  1999-12       Impact factor: 2.571

2.  Adaptive randomized phase II design for biomarker threshold selection and independent evaluation.

Authors:  Lindsay A Renfro; Christina M Coughlin; Axel M Grothey; Daniel J Sargent
Journal:  Chin Clin Oncol       Date:  2014-03

3.  Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines.

Authors:  Wen Li; Cong Chen; Xiaoyun Li; Robert A Beckman
Journal:  Stat Med       Date:  2017-03-17       Impact factor: 2.373

4.  Accounting for selection and correlation in the analysis of two-stage genome-wide association studies.

Authors:  David S Robertson; A Toby Prevost; Jack Bowden
Journal:  Biostatistics       Date:  2016-03-18       Impact factor: 5.899

5.  Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology.

Authors:  Werner Brannath; Emmanuel Zuber; Michael Branson; Frank Bretz; Paul Gallo; Martin Posch; Amy Racine-Poon
Journal:  Stat Med       Date:  2009-05-01       Impact factor: 2.373

6.  Confidence intervals for the selected population in randomized trials that adapt the population enrolled.

Authors:  Michael Rosenblum
Journal:  Biom J       Date:  2013-04-03       Impact factor: 2.207

7.  Estimation after subpopulation selection in adaptive seamless trials.

Authors:  Peter K Kimani; Susan Todd; Nigel Stallard
Journal:  Stat Med       Date:  2015-04-22       Impact factor: 2.373

8.  Point estimation following two-stage adaptive threshold enrichment clinical trials.

Authors:  Peter K Kimani; Susan Todd; Lindsay A Renfro; Nigel Stallard
Journal:  Stat Med       Date:  2018-05-31       Impact factor: 2.373

9.  Simultaneous confidence intervals that are compatible with closed testing in adaptive designs.

Authors:  D Magirr; T Jaki; M Posch; F Klinglmueller
Journal:  Biometrika       Date:  2013-12-01       Impact factor: 2.445

10.  One-stage and two-stage designs for phase II clinical trials with survival endpoints.

Authors:  John Whitehead
Journal:  Stat Med       Date:  2014-05-12       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.